ImmunoGen

To see an up-to date selection of historical analyses and insights on ImmunoGen, visit our new, dynamically updated Company Summary report pages for ImmunoGen.

As a Guest User, you will have FREE access to a selection of historical analyses and insights from EvaluatePharma®.

How to access FREE content

  • Search the content using the search box at the top of every page
  • Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
  • Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar

Register for FREE to access even more content including 2007 Product Sales and Rankings.

A small selected sample of reports and related news headlines for ImmunoGen are available below. Free sample reports are also available for other Companies.

To find out how you can access more detailed information on ImmunoGen, or on any other Company covered by EvaluatePharma® Contact Us today.

NEWS - Selected Product News Headlines (as of 11 June 2008)
Seattle deal and ImmunoGen data mark growing interest in conjugate field   (ImmunoGen)   (Invalid Date)
ImmunoGen, Inc. Announces Positive Trastuzumab-DM1 Clinical Data Reported at the San Antonio Breast Cancer Symposium   (ImmunoGen)   (Invalid Date)
New Phase II Study Showed Trastuzumab-DM1 Shrank Tumors in Women With Highly Advanced HER2-positive Breast Cancer   (Roche)   (Invalid Date)
SAR3419 Phase I Study Resultsin Non-hodgkin's Lymphoma at ASH   (ImmunoGen)   (Invalid Date)
Immunoconjugate BT-062 Shows First Data of Clinical Efficacy   (Biotest)   (Invalid Date)
ImmunoGen, Inc. Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Multiple Myeloma   (ImmunoGen)   (Invalid Date)
Event - ImmunoGen's antibody drug conjugates shaping up for scrutiny   (ImmunoGen)   (Invalid Date)
ImmunoGen, Inc. Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Merkel Cell Carcinoma   (ImmunoGen)   (Invalid Date)
ImmunoGen, Inc. Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics   (ImmunoGen)   (Invalid Date)
ImmunoGen Announces Encouraging New Clinical Data with the Company's IMGN901 Compound in the Treatment of Small-Cell Lung Cancer   (ImmunoGen)   (Invalid Date)
ImmunoGen, Inc. Elects to Discontinue Further Internal Development of Its IMGN242 Compound   (ImmunoGen)   (Invalid Date)
ImmunoGen, Inc. Announces Encouraging Trastuzumab-DM1 Phase II Clinical Findings Presented at ASCO   (ImmunoGen)   (Invalid Date)
New form of Targeted Therapy Offers Further Hope to Patients With Advanced HER2-Positive Breast Cancer   (Roche)   (Invalid Date)
ImmunoGen, Inc. Earns Milestone Payment with Genentech's Start of Trastuzumab-DM1 (T-DM1) Phase III Clinical Testing   (ImmunoGen)   (Invalid Date)

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts.

Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®.

Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.

Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.